NLRC5在弥漫性大B细胞淋巴瘤中的作用机制

doi:10.3760/cma.j.issn.1673-422X.2015.02.021

摘要/Abstract

摘要： 弥漫性大B细胞淋巴瘤（DLBCL）是我国最常见的恶性淋巴瘤，大多首发自淋巴结。研究发现，核苷酸结合寡聚化结构域样受体（NLR）家族成员NLRC5在淋巴系细胞中表达明显，其可能是淋巴细胞肿瘤发生的重要基础。并且NLRC5能阻断信号传导途径中的核心组分核转录因子κB（NFκB），影响肿瘤发生发展。同时NFκB的持续活化是DLBCL细胞生存的必要条件。因此，NLRC5很可能具有抑制过度炎症反应，进而抑制DLBCL的功能，其有望成为DLBCL免疫疗法的新靶点。

关键词: 淋巴瘤, 大B细胞, 弥漫性, NF-&kappa, B, 基因, MHCⅠ类, NLRC5

Abstract: Diffuse large Bcell lymphoma (DLBCL) is the most common malignant lymphoma in China, which mostly starting from the lymph nodes. The studies find that the expression of NLRC5, member of nucleotidebinding oligomerization domainlike receptor (NLR) family, is evident in the lymphoid cells, which is likely to be an important basis for lymphocyte tumorigenesis. NLRC5 can block the nuclear factorκB (NFκB), a core component of signal transduction pathway, and affect the development of tumor. While continuing activation of NFκB is a necessary condition for DLBCL cell survival. Therefore, NLRC5 is likely to inhibit excessive inflammation, thereby inhibiting the function of DLBCL, which promises to be a new target for immunotherapy treatment of DLBCL.

Key words: Lymphoma, large B-cell, diffuse, NF-kappaB, Genes, MHC class Ⅰ, NLRC5

全彦龙,周英琼. NLRC5在弥漫性大B细胞淋巴瘤中的作用机制[J]. 国际肿瘤学杂志, 2015, 42(2): 157-160.

Quan Yanlong, Zhou Yingqiong. Mechanism of NLRC5 in diffuse large B-cell lymphoma[J]. Journal of International Oncology, 2015, 42(2): 157-160.

参考文献

［1］ Meissner TB, Li A, Biswas A, et al. NLR family member NLRC5 is a transcriptional regulator of MHC class Ⅰ genes［J］. Proc Natl Acad Sci USA, 2010, 107(31): 13794-13799. ［2］ Ting JP, Kastner DL, Hoffman HM. CATERPILLERs,pyrin and hereditary immunological disorders［J］. Nat Rev Immunol, 2006, 6(3): 183-195. ［3］ Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition［J］. Nat Immunol, 2011, 12(2): 121-128. ［4］ Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large Bcell lymphoma defined by gene expression profiling［J］. Clin Cancer Res, 2005, 11(1): 28-40. ［5］ Tong Y, Cui J, Li Q, et al. Enhanced TLRinduced NFκB signaling and type Ⅰ interferon responses in NLRC5 deficient mice［J］. Cell Res, 2012, 22(5): 822835. ［6］ Staehli F, Ludigs K, Heinz LX, et al. NLRC5 deficiency selectively impairs MHC class Ⅰdependent lymphocyte killing by cytotoxic T cells［J］. J Immunol, 2012, 188(8): 3820-3828. ［7］ Benko S, Magalhaes JG, Philpott DJ, et al. NLRC5 limits the activation of inflammatory pathways［J］. J Immunol, 2010, 185(3): 1681-1691. ［8］ Kuenzel S, Till A, Winkler M, et al. The nucleotidebinding oligomerization domainlike receptor NLRC5 is involved in IFNdependent antiviral immune responses［J］. J Immunol, 2010, 184(4): 1990-2000. ［9］ Neerincx A, Lautz K, Menning M, et al. A role for the human nucleotidebinding domain, leucinerich repeatcontaining family member NLRC5 in antiviral responses［J］. Biol Chem, 2010, 285(34): 26223-26232. ［10］ Sen R, Baltimor D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences［J］. Cell, 1986, 46(5): 705-716. ［11］ Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NFkappaB and type Ⅰ interferon signaling pathways［J］. Cell, 2010, 141(3): 483-496. ［12］ Kumar H, Pandey S, Zou J, et al. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections［J］. J Immunol, 2011, 186(2): 994-1000. ［13］ Compaqno M, Lim Wk, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large Bcell lymphoma［J］. Nature, 2009, 459(7247): 717-721. ［14］ Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with highaccuracy［J］. Clin Cancer Res, 2009, 15(17): 5494-5502. ［15］ Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ difuse large Bcell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cel1［J］. Blood, 2003, 101(2): 699-702. ［16］ Neerincx A, Castro W, Guarda G, et al. NLRC5, at the heart of antigen presentation［J］. Front Immunol, 2013, 4: 397. ［17］ Meissner TB, Li A, Liu YJ, et al. The nucleotidebinding domain of NLRC5 is critical for nuclear import and transactivation activity［J］. Biochem Biophys Res Commun, 2012, 418(4): 786-791. ［18］ Neerincx A, Rodriguez GM, Steimle V, et al. NLRC5 controls basal MHC class Ⅰ gene expression in an MHC enhanceosomedependent manner［J］. J Immunol, 2012, 188(10): 49404950. ［19］ Meissner TB, Liu YJ, Lee KH, et al. NLRC5 cooperates with the RFX transcription factor complex to induce MHC class Ⅰ gene expression［J］. J Immunol, 2012, 188(10): 49514958. ［20］ Yao Y, Wang Y, Chen F, et al. NLRC5 regulates MHC class Ⅰ antigen presentation in host defense against intracellular pathogens［J］. Cell Res, 2012, 22(5): 836-847. ［21］ Biswas A, Meissner TB, Kawai T, et al. Cutting edge: impaired MHC class Ⅰ expression in mice deficient for Nlrc5/Class Ⅰ transactivator［J］. J Immunol, 2012, 15, 189(2): 516-520. ［22］ Ting JP, Willingham SB, Bergstralh DT. NLRs at the intersection of cell death and immunity［J］. Nat Rev Immunol, 2008, 8(5): 372-379. ［23］ Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let7 MicroRNA, and IL6 links inflammation to cell transformation［J］. Cell, 2009, 139(4): 693-706.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[4]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[5]	李丹, 李睿尧, 李膺函, 于秀艳, 吴雪峰. 血清miR-19b、miR-744-5p水平在非小细胞肺癌诊断中的临床价值[J]. 国际肿瘤学杂志, 2024, 51(2): 83-88.
[6]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[7]	叶彤彤, 吴泽宇, 席文一, 王芝微, 江晓春, 赵晨辉. ABRACL在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 544-547.
[8]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[9]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇. Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[10]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣. 三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[11]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[12]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[13]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[14]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.